-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec Content Team Editors Today, Arvinas announced the latest results of Phase 1 and Phase 2 clinical trials of its PROTAC protein degrader bavdegalutamide (ARV-110) targeting the androgen receptor (AR)
.
Trial results show that bavdegalutamide exhibits potent anticancer activity in the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients with AR T878X/H875Y (T878X=T878A or T878S) mutations
.
These data support the potential of bavdegalutamide to be approved for the treatment of specific patient populations defined by molecular biology using the accelerated approval pathway, according to the press release
.
The company plans to initiate pivotal clinical trials by the end of 2022
.